Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$9.03
+1.9%
$6.54
$3.91
$13.99
$621.36M1.61819,335 shs822,461 shs
Quantum-Si incorporated stock logo
QSI
Quantum-Si
$1.66
-7.3%
$1.43
$0.61
$5.77
$304.61M2.8710.92 million shs8.18 million shs
Transcat, Inc. stock logo
TRNS
Transcat
$79.16
+2.3%
$82.37
$67.56
$147.12
$737.61M0.7586,975 shs184,140 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$10.41
-1.6%
$8.75
$6.78
$24.76
$1.28B1.992.55 million shs2.24 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
+1.92%+1.01%+64.48%+38.50%-3.11%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
-7.26%-4.60%+9.21%+22.06%+9.21%
Transcat, Inc. stock logo
TRNS
Transcat
+2.29%+1.51%-0.16%+9.08%-36.65%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-1.61%+10.51%+14.14%+0.68%-51.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.2146 of 5 stars
3.52.00.00.03.31.70.0
Quantum-Si incorporated stock logo
QSI
Quantum-Si
2.6309 of 5 stars
3.32.00.00.03.22.50.6
Transcat, Inc. stock logo
TRNS
Transcat
2.9256 of 5 stars
3.33.00.00.01.71.71.9
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.2032 of 5 stars
4.21.00.04.81.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.38181.01% Upside
Quantum-Si incorporated stock logo
QSI
Quantum-Si
2.67
Moderate Buy$3.48109.34% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$114.0044.01% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.38
Hold$15.8151.85% Upside

Current Analyst Ratings Breakdown

Latest QSI, TXG, TRNS, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/29/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/24/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/19/2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.50
5/19/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $18.00
5/16/2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/15/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$14.00 ➝ $14.00
5/13/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
5/12/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$7.50 ➝ $6.50
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$56.04M11.09N/AN/A$5.66 per share1.60
Quantum-Si incorporated stock logo
QSI
Quantum-Si
$3.44M88.47N/AN/A$1.92 per share0.86
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.65$2.92 per share27.14$30.19 per share2.62
10x Genomics, Inc. stock logo
TXG
10x Genomics
$624.66M2.05N/AN/A$5.81 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)
Quantum-Si incorporated stock logo
QSI
Quantum-Si
-$95.96M-$0.68N/AN/AN/A-3,968.84%-36.96%-33.57%8/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.5642.7930.10N/A6.22%7.23%5.67%8/4/2025 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$182.63M-$1.30N/AN/AN/A-29.90%-25.40%-19.69%8/6/2025 (Estimated)

Latest QSI, TXG, TRNS, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/15/2025Q1 2025
Quantum-Si incorporated stock logo
QSI
Quantum-Si
-$0.17-$0.11+$0.06-$0.11$0.96 million$0.84 million
5/8/2025Q1 2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.45-$0.36+$0.09-$0.28$131.91 million$154.88 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quantum-Si incorporated stock logo
QSI
Quantum-Si
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Quantum-Si incorporated stock logo
QSI
Quantum-Si
N/A
13.42
13.15
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.97
4.26

Institutional Ownership

CompanyInstitutional Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
39.90%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.46%
Quantum-Si incorporated stock logo
QSI
Quantum-Si
30.04%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
10x Genomics, Inc. stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Quantum-Si incorporated stock logo
QSI
Quantum-Si
150183.50 million99.84 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.32 million9.10 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,240123.13 million108.91 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$9.03 +0.17 (+1.92%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$9.04 +0.01 (+0.06%)
As of 06/13/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quantum-Si stock logo

Quantum-Si NASDAQ:QSI

$1.66 -0.13 (-7.26%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.67 +0.01 (+0.60%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

Transcat stock logo

Transcat NASDAQ:TRNS

$79.16 +1.77 (+2.29%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$79.01 -0.15 (-0.19%)
As of 06/13/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$10.41 -0.17 (-1.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$10.56 +0.15 (+1.39%)
As of 06/13/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.